Inovio Pharmaceuticals stock approaches its October FDA test

Inovio Pharmaceuticals stock (ISIN US45773H2013) had a market capitalization of USD 84.3 million on September 30, 2026, with a 52-week range of USD 0.56 to USD 2.72. The next major company milestone is the October 30, 2026 FDA decision date for INO-3107.

FDA decision sets the timeline

INOVIO is developing DNA medicines for serious diseases, including recurrent respiratory papillomatosis, an HPV-related disease of the respiratory tract. The company says its Biologics License Application for INO-3107 is under FDA review, making the regulatory date a central event for the clinical-stage biotechnology business.

According to Tickeron on September 17, 2026, the FDA set October 30, 2026 as the target Prescription Drug User Fee Act date for INO-3107. The product is being reviewed for recurrent respiratory papillomatosis, so the decision could determine whether INOVIO moves from development toward commercialization.

Quarterly loss beats consensus

INOVIO reported diluted EPS of USD -0.07 for Q2 2026, compared with a consensus estimate of USD -0.22, according to MarketBeat in its September 29, 2026 report. The USD 0.15 difference shows that the quarterly loss was narrower than the consensus expectation, although the company remains unprofitable.

The same MarketBeat report said Jefferies raised its rating from Hold to Positive and increased its price target from USD 1.80 to USD 3.00 on August 13, 2026. That target is materially above the September 30 primary-market price, but it reflects analyst expectations rather than a company forecast.

Nasdaq range keeps risk visible

Inovio was last at USD 1.22 on Nasdaq on September 30, 2026 at 4:00 p.m. ET. The price stood USD 1.50 below the USD 2.72 52-week high, leaving the regulatory decision and the companys cash needs as the key variables for the stock.

More news and analyses on Inovio Pharmaceuticals stock